Loading news...
Members of Congress have been actively buying up Bitcoin (CRYPTO: <
Ferguson Wellman Capital Management Inc. lessened its position in Abbott Laboratories (NYSE: ABT) by 21.6% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 186,305 shares of the healthcare product maker's stock after selling 51,312 shares during the quarter. Ferguson Wellman Capital
Dividend aristocrats get plenty of attention, but most of the time the spotlight falls on the big names like Johnson & Johnson (NYSE:JNJ), Coca-Cola (NYSE:KO), and Procter & Gamble (NYSE:PG), among others.
CoreCap Advisors LLC increased its position in shares of Abbott Laboratories (NYSE: ABT) by 15.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,651 shares of the healthcare product maker's stock after buying an additional 4,017 shares during the quarter. CoreCap Advisors
Absolute Software Co. (ABT.TO) (TSE: ABT - Get Free Report)'s stock price passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$0.00 and traded as high as C$22.79. Absolute Software Co. (ABT.TO) shares last traded at C$22.79, with a volume of 541 shares traded. Absolute Software
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Libre), are driving over 12% segment growth, with Diabetes Care revenues surpassing $2B and growing 17%. ABT reaffirmed 2025 organic growth guidance of 7.5%–8% and EPS of $5.12–$5.18, with consistent, low-volatility earnings growth expected through 2027.
The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties. LAS VEGAS, NEVADA / ACCESS Newswire / January 7, 2026 / Sentinel Net Lease (the "Company") announced today that Sentinel Opportunity Fund I, LP (the "Fund") has closed on the acquisitions of two mission-critical commercial properties leased to Abbott Laboratories and V3 Engineering.
DSM Capital Partners LLC increased its holdings in Abbott Laboratories (NYSE: ABT) by 7.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 832,780 shares of the healthcare product maker's stock after acquiring an additional 60,432 shares
Cerity Partners LLC lowered its stake in shares of Abbott Laboratories (NYSE: ABT) by 0.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,530,328 shares of the healthcare product maker's stock after selling 8,052 shares
First Merchants Corp lowered its position in shares of Abbott Laboratories (NYSE: ABT) by 9.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,655 shares of the healthcare product maker's stock after selling 4,453 shares during the quarter. First
Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
In the latest trading session, Abbott (ABT) closed at $126.45, marking a +1.82% move from the previous day.
ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.
Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology4 Abbott is launching Libre Assist, available at no additional cost within the Libre app,5 during CES® 2026 ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the millions of people living with diabetes in the U.S. better understand how the foods they eat affect their glucose levels.
Railway Pension Investments Ltd decreased its position in Abbott Laboratories (NYSE: ABT) by 67.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,700 shares of the healthcare product maker's stock after selling 156,200 shares during the quarter. Railway Pension
Asset Management One Co. Ltd. raised its position in shares of Abbott Laboratories (NYSE: ABT) by 2.4% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 858,834 shares of the healthcare product maker's stock after buying an additional 19,966 shares during the
Citadel Investment Advisory Inc. reduced its position in shares of Abbott Laboratories (NYSE: ABT) by 89.9% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,064 shares of the healthcare product maker's stock after selling 81,100 shares during the quarter. Citadel Investment
Johnson & Johnson and Abbott Laboratories are diversified healthcare companies with attractive prospects. Both have raised their dividends for over 50 consecutive years.
American National Bank and Trust lessened its stake in shares of Abbott Laboratories (NYSE: ABT) by 39.9% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,014 shares of the healthcare product maker's stock after selling 4,651 shares during the